The FDA has updated the label for ibrutinib to include new overall survival data, an indication for the BTK inhibitor in combination with bendamustine/rituximab, and a new indication for patients with small lymphocytic lymphoma with a 17p deletion.
Jan Burger, MD, PhD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Jan Burger, MD, PhD
The FDA has updated the label for ibrutinib (Imbruvica) to include new overall survival (OS) data, an indication for the BTK inhibitor in combination with bendamustine/rituximab (BR), and a new indication for patients with small lymphocytic lymphoma (SLL) with a 17p deletion, according to AbbVie, which codevelops ibrutinib with Janssen Biotech.
The new OS data are from the phase III RESONATE-2 trial,1which compared ibrutinib with chlorambucil for untreated patients with chronic lymphocytic leukemia (CLL). Additionally, the ibrutinib/bendamustine (BR) indication was based upon data from the phase III HELIOS trial,2which compared the triplet with BR alone
“This update helps to affirm the established efficacy, safety, and tolerability of this therapy for treatment of patients with CLL/SLL, both as a monotherapy or in combination with other agents,” RESONATE-2 lead investigator Jan Burger, MD, PhD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, said in a statement. “It reflects the growing body of clinical evidence supporting this therapy as a potential treatment option for people living with CLL/SLL."
The RESONATE-2 trial was the basis for the FDA’s March 2016 approval of ibrutinib for the treatment of patients with CLL in the first-line setting. The trial included 269 treatment-naïve patients aged ≥65 years with CLL or SLL. The median age was 73 years. Patients with the 17p deletion were excluded from the study.
The study’s primary endpoint was progression-free survival (PFS) as evaluated by an independent review committee (IRC). OS and overall response rate (ORR) were secondary outcome measures.
The IRC found that, compared with chlorambucil, ibrutinib led to an 84% reduction in the risk of progression or death (HR, 0.16; 95% CI, 0.09-0.28); investigators calculated that risk reduction as 91%. At a median follow-up of 18.4 months, the median PFS was not yet reached with ibrutinib versus 19 months with chlorambucil (P<.0001) .The median 18-month PFS rates were 94% and 45%, respectively, and the results were consistent across subgroups.
At a median follow-up of 28.1 months, 41% of patients in the chlorambucil arm had crossed over at progression to receive ibrutinib. At this analysis, ibrutinib reduced the risk of death by 56% versus chlorambucil (HR, 0.44; 95% CI, 0.21-0.92).
As per IRC review, ORR was 86% with ibrutinib, which included complete responses (CR) for 4.4% of patients. In the chlorambucil arm, the ORR was 35.3% with a CR rate of 1.5%. Investigator-assessed ORR was 90.4%, with 9.6% of those being CRs, versus 35.3%, with 4.5% of those being CRs, respectively.
The double-blind phase III HELIOS trial randomized 578 previously treated patients with measurable relapsed/refractory CLL/SLL to BR for a maximum of six cycles plus either placebo (n = 289) or 420 mg/day of ibrutinib (n = 289). Overall, 83% and 78% of patients in the ibrutinib and placebo arms completed the full six cycles of BR, respectively.
The median patient age was 64 years and patients had received an average of two prior therapies. Patients with 17p deletions (>20% of cells) were not included in the study. PFS was the primary outcome measure, with secondary endpoints focused on OS and ORR.
At a median follow-up of 17.2 months, the triplet reduced the risk of disease progression or death by 80% versus BR alone (HR, 0.20; 95% CI, 0.15-0.28;P<.0001). Median PFS with ibrutinib was not yet reached, as compared with 13.3 months for patients receiving BR alone. The PFS benefit held up across subgroups of high-risk patients.
ORR was 82.7% in the ibrutinib arm versus 67.8% in the control group (P<.0001). Complete response (CR) rates (including CR with incomplete blood count recovery) were 10.4% versus 2.8% with ibrutinib versus placebo, respectively. The OS analysis showed a nonsignificant 37% reduction in the risk of death (P= .0598).
The toxicity profile was similar between the two study arms, and the AEs in the triplet arm were consistent with previously reported safety outcomes for ibrutinib and BR. The most frequently reported all-grade AEs in the ibrutinib versus the placebo arm were neutropenia (58.2% vs 54.7%), nausea (36.9% vs 35.2%), diarrhea (35.5% vs 23.7%), thrombocytopenia (30.7% vs. 24.4%), pyrexia (24.7% vs. 22%), anemia (22.6% vs 28.9%), and fatigue (21.6% vs 22.6%). Neutropenia (53.7% vs 50.5%) and thrombocytopenia (15.0% in each arm) were the most commonly reported grade 3/4 AEs.
Grade ≥3 hemorrhage occurred in 3.8% of patients receiving the triplet, compared with 1.7% for those receiving BR alone. Grade 3/4 major hemorrhage and atrial fibrillation rates were 2.1% versus 1.7% and 2.8% versus 0.7% in the ibrutinib versus placebo arms, respectively. AEs led to treatment discontinuation in 14.2% and 11.8% of patients in the triplet and control arms, respectively.
“We are pleased the FDA has added the survival data observed with Imbruvica as a first-line therapy for CLL to its prescribing information and that the indication has been expanded to include patients with SLL. Moreover, the positive results seen in the HELIOS study provide additional evidence supporting the compelling safety and efficacy seen with Imbruvica in CLL and SLL patients,” Danelle James, MD, head of Oncology at Pharmacyclics, a division of Abbie, said in statement. "We believe the Imbruvica label is very strong for the treatment of certain hematologic malignancies and is now reinforced not only by data evaluating its use as a single agent, but also in combination with other commonly used chemotherapy regimens."